To investigate the clinical relevance of the distinct modes of action of fingolimod and IFN-β therapies in MS patients with various Sema4A levels, we first examined the correlation of serum Sema4A levels and fingolimod efficacy among the patients recruited in our study. Here, SEMA4A is linked to myeloid sarcoma.